Faculty Bibliography

The prevalence of nocturia in patients with multiple sclerosis (MS) is high, ranging from 20.9% to 48.8% in this population. Its underlying pathophysiology is complex and different from the non-neurogenic population. In the MS population, the pathophysiology may involve neurogenic lower urinary tract dysfunction (NLUTD) such as detrusor overactivity (NDO), detrusor-sphincter dyssynergia, or detrusor underactivity resulting in reduced bladder capacity. Nocturnal polyuria is also a significant contributor to the pathogenesis of nocturia in MS patients and may be the result of specific mechanisms such as nocturnal hypertension through autonomic cardiovascular dysfunction or lack of diurnal variation of antidiuretic hormone production (ADH) due to demyelinating lesions of the spinal cord. Nocturia might be particularly burdensome in MS patients by contributing to fatigue, a common and highly debilitating symptom in this population. There is likely a complex and multidirectional relationship between nocturia, other sleep disorders, and fatigue in the MS population that has yet to be explored. The assessment of nocturia in MS should rely upon a thorough history and physical examination. Urinalysis should be done to rule out urinary tract infection, a frequency-volume chart might help elucidating the underlying mechanisms, and post-void residual volume may be of interest to screen for urinary retention that could be asymptomatic in MS patients. Other tests such as urodynamics or polysomnography are indicated in selected patients. The treatment should be tailored to the underlying cause. The first steps involve behavioral interventions and treatment of cofactors. When possible, the predominant mechanism should be addressed first. In case of predominant NDO, antimuscarinics and beta-3 agonists should be offered as a first-line treatment and intradetrusor injections of botulinum toxin as a second-line treatment. In cases of incomplete bladder emptying, clean-intermittent self-catheterization is often used as part of multiple other interventions. In cases of nocturnal polyuria, desmopressin may be offered, inclusive of use of newer formulations (desmopressin acetate nasal spray, desmopressin orally disintegrated tablet) in countries where they are approved.

Background: Clinical observations and emerging studies suggest that African American (AA) people with multiple sclerosis (MS) tend to fare worse than their Caucasian American (CA) counterparts. Existing studies are limited by few AA participants and could often not evaluate other potential con-tributing factors. Objective: To compare socio-economic and relevant clini-cal characteristics of a large population of AA and CA people with MS. Methods: MS PATHS is a Biogen-sponsored network of 10 large MS centers located in the US (7) and Europe (3); standardized collection of socio-demographic characteristics, including self-reported race and clinical and disease information are acquired at least annually during routine clinic visits. We included US-based MS PATHS participants with self-reported AA and CA race who provided socio-economic and baseline MS characteristics. We compared AA vs. CA with respect to education, employment, and insurance status and MS characteristics including self-reported disability (via Patient Determined Disease Steps [PDDS]) and objective assessments of neurological function (via walking speed, electronically-assessed manual dexterity, and processing speed). To compare socio-economic characteristics between AAs and CAs, we fit generalized linear regression models. For PDDS, we fit multinomial regression models comparing severe vs. mild and moderate vs. mild disability. For neurological assessments, we fit linear regression models. Models for PDDS and neurologic outcomes were adjusted for age, sex, disease subtype and duration, employment, and insurance status. Results: Of US-based eligible participants in MS PATHS, 909 (14%) identified as AAs while 5842 (86%) identified as CAs and were included in the analyses. AAs were younger (mean 45.6y [SD:12.5] vs. 49.7y [12.3y]; p<0.0001), had fewer years of education (14.1y [2.8] vs. 14.8y [2.6]; p<0.0001), had Medicaid health insurance (20% vs. 7%; P<0.0001), and were currently on disability or not working (39% vs. 29%; p<0.0001) relative to CAs. With respect to MS characteristics, AAs had a 58% multivariable-adjusted higher odds of severe vs. mild disability relative to CAs (OR: 1.58; 95% CI: 1.22-2.04). They also had significantly slower walking and manual dexterity speeds and lower cognitive performance scores relative to CAs (multivariable-adjusted mean difference [95% CI]: 25-foot walking speed: 1.11 seconds [1.07-1.14]; manual dexterity: 1.07 seconds [1.05-1.08]; processing speed scores:-4.23 [-5.00-3.47]. Conclusions: In this large sample, self-reported AA identity was associated with indicators of lower socio-economic status and with greater MS severity across a broad array of neurological assessments

BACKGROUND: Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White patients enrolled in these RCTs to allow for subgroup analysis based on race. Efficacy and tolerability of DMF therapy across various racial groups is unknown. METHODS: Retrospective chart review was performed on all patients with RRMS who were started on DMF in two tertiary multiple sclerosis (MS) clinics. Efficacy and tolerability of DMF was compared across three self-identified racial groups: White-American (WA), African-American (AA) and Hispanic-American (HA). RESULTS: A total of 390 RRMS patients were included in the study: 261 (66.9%) WA, 69 (17.7%) AA and 52 (13.3%) HA. When comparing 'pre-DMF' (1 year) and 'on DMF' (mean follow up of 14 months) periods, statistically significant reduction in rates of annualized relapses (WA from 0.44 to 0.19, AA from 0.39 to 0.15, and HA from 0.39 to 0.14; no differences between groups), new T2 lesions (WA from 45% to 23%, AA from 39% to 23%, HA from 52% to 26%; no difference between groups), and Gd+ lesions (WA from 25% to 13%, AA from 24% to 7%, HA from 23% to 12%; no difference between groups) were seen. DMF was relatively well tolerated across all groups, with an overall discontinuation rate of 20% (no difference between the three groups). CONCLUSION: Efficacy of DMF in our clinic population did not differ across three major ethnic groups, WA, AA and HA, and was comparable with results observed in the pivotal studies. These 'real-life' data suggest that race is not a factor that needs to be taken into account when initiating DMF.